

January 2018 APC Decisions

Medicine	Traffic light status	Indication	Other Information
Trimbow® (Formoterol fumarate, beclometasone dipropionate and glycopyrronium bromide, Chiesi Ltd)	Deferred	COPD	Further clarification being sought. Several more triple therapy inhalers are being developed and the NICE COPD guideline is due for a review later in the year.
Freestyle® Libre (Abbott Diabetes Care)	Deferred	Type 1 Diabetes	Predicted cost impact exceeded the mandated threshold, therefore the decision has been delegated back to the CCGs

For a full explanation of the Traffic Light definitions, please refer to the [Joint Formulary website](#)

News from the APC

Ratified at the meeting:

(Please note the final documents will be uploaded and available on the APC website within the next 2 weeks to allow for final editing)

- ***Inflammatory Bowel Disease, Azathioprine and mercaptopurine information sheets (update)***
- ***Apomorphine prescribing information sheet and Parkinsons' Disease SCP (Update)***
- ***[The Eye Lubricant formulary](#) had been updated since publication in September 2017. For the most up to date version see the APC website***

[NICE asthma Guidelines \(NG80\)](#)

Following publication of the updated NICE guidelines, the APC along with the local respiratory clinicians have considered the changes and the differences between this and the local Nottinghamshire guidelines.

The local treatment summary is based on the BTS/Sign guidelines rather than NICE guidelines. It was agreed that it may be confusing and detrimental to asthma control to make any changes locally until there is national agreement that NICE guidelines replace BTS/SIGN guidelines.

No Changes to the local guidelines will therefore be made currently.

Horizon Scanning, Formulary amendments and traffic light changes

Formulary amendments

- Promixin® (Colistimethate nebules) - reclassified to RED for new patients and AMBER 2 for existing patients
- Isotrex® Gel - Reclassified as GREY following discontinuation
- Circadin® (Melatonin MR capsules) - “intellectual disabilities” clarified in line with the definition within [NICE CG 11](#).
- Rizatriptan - added to the formulary as GREEN as a cost effective choice
- Prednisolone Foam Enema - Reclassified as GREY due to the availability of more cost effective options

Horizon scanning

- Elebrato® inhaler - Classified as Grey while a submission is awaited
- Testavan® gel- Classified as Grey while a submission is awaited

Current work in development

- Emollient Formulary (Review)
- Motor Neurone Disease, Riluzole SCP (Review)
- Shared care development process (New)
- Prescribing Policy (Review)
- Anticoagulation in AF guidelines (Review)
- Atypical antipsychotics information sheets (Review)
- Parkinson's disease prescribing information sheets (Review)

Upcoming NICE guidance

TITLE	GUIDELINE/TA	EXPECTED DATE
Hyperuricaemia (chronic) in gout - lesinurad	Guideline	Feb 2018
Heavy menstrual bleeding (update)	Guideline	Feb 2018
Attention deficit hyperactivity disorder	Guideline	March 18
Depression in adults: treatment and management	Guideline	March 18
Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism	Guideline	March 18

The work of the NAPC is supported and managed by the interface team below. They can be contacted via MACCG.NottsAPC@nhs.net if you would like to make a submission or have any queries.

Laura Catt, Prescribing Interface Advisor, NHS Mansfield and Ashfield CCG

Lynne Kennel, Specialist Interface and Formulary Pharmacist, Sherwood Forest Hospitals NHS Foundation Trust

Irina Varlan, Specialist Interface and Formulary Pharmacist, Nottingham University Hospitals NHS Trust